Breaking News

European Court Orders Russia to Pay €1.87 Billion for Yukos Seizure
Tweet TWEET

New Teva Representative Joins Mesoblast Board of Directors

          New Teva Representative Joins Mesoblast Board of Directors

PR Newswire

MELBOURNE, Australia, May 10, 2012

MELBOURNE, Australia, May 10, 2012 /PRNewswire/ -- Global regenerative
medicine company Mesoblast Limited (ASX: MSB) today announced the appointment
of Dr Ben-Zion Weiner, Special Adviser to the CEO of Teva Pharmaceutical
Industries Ltd, as a non-executive Director of Mesoblast, effective
immediately.

Dr Weiner has been Teva's head of global research and development for over
three decades, most recently as Chief R&D Officer and a member of the Teva
Executive Committee. In this role, he has directly overseen all pharmaceutical
R&D and innovative branded product pipeline development.

Dr Weiner has been responsible for the development of hundreds of generic
products for the US, EU and other markets. In parallel, he has been
responsible for the development and regulatory approval of Teva's innovative
product portfolio. Dr Weiner has twice been the recipient of the Rothschild
prize for innovation, including for the commercialization of Copaxone in the
treatment of multiple sclerosis.

Dr Weiner said: "I am happy and proud to be a Board member of Mesoblast. I
trust that stem cell technology is the future of medicine, and that Mesoblast
is at the cutting edge of this exciting new field.

"I believe that Mesoblast's unique technology and professional execution
capabilities have the potential to deliver multiple innovative biologic
products across a broad range of clinical indications," added Dr Weiner.

Mesoblast Chairman, Mr Brian Jamieson, said: "Dr Weiner's extensive
pharmaceutical industry experience and his current role as Special Adviser to
the Teva CEO make him a very valuable and strategic addition to the Board. We
also acknowledge the important contributions and insights provided by Teva's
retiring board representative, Kevin Buchi, and wish him well.

"As Mesoblast expands its clinical product portfolio and approaches product
commercialization, we will continue to broaden the mix of skills and
international expertise of our Directors to ensure that the Board is in the
best position to deliver maximal shareholder value."

About Mesoblast
Mesoblast Limited (ASX: MSB) is a world leader in commercialising biologic
products for the broad field of regenerative medicine. Mesoblast has the
worldwide exclusive rights for a series of patents and technologies developed
over more than 10 years relating to the identification, extraction, culture
and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com

For further information, please contact:
Julie Meldrum
Corporate Communications
Mesoblast Limited
E: julie.meldrum@mesoblast.com

SOURCE Mesoblast